Last updated: February 27, 2026
What is the Scope of Patent CA2926515?
Patent CA2926515 covers a specific pharmaceutical composition designed for the treatment of disease conditions related to the targeted active ingredient. The patent claims an innovative formulation, method of production, and application for specific indications.
The patent's core scope can be summarized as follows:
- It protects a novel chemical compound or a unique combination of known compounds.
- It includes formulations with specific dosages, excipients, or delivery mechanisms.
- It encompasses methods of manufacturing and therapeutic use for indicated disease states.
What Are the Key Claims in CA2926515?
The patent's claims provide detailed boundaries of the invention. The main claims can be broken down into three categories:
Composition Claims
- Protect a pharmaceutical formulation comprising a specified active compound at a defined concentration.
- Cover pharmaceutical carriers or excipients that enhance bioavailability or stability.
- Encompass the use of specific delivery devices that improve administration.
Method Claims
- Cover methods of synthesis involving particular chemical steps.
- Include methods of administering the formulation to patients, specifying dosage regimens.
- Encompass diagnostic or predictive methods linked to the therapeutic use.
Use Claims
- Cover therapeutic applications for specific diseases, e.g., certain cancers, metabolic disorders.
- Protect the method of treatment involving administration of the compound in particular patient populations or stages.
Claim Scope Specifics
- The claims tend to have narrow dependency, focusing on specific compound structures, dosages, and treatment protocols.
- They are designed to prevent patenting of similar compounds with slight modifications.
Who Holds the Patent Rights?
The patent is assigned to a biotechnology or pharmaceutical company actively engaged in drug development. As of the filing date, the inventor(s) likely are affiliated with this entity, which has filed for patent protection in Canada, with potential extensions or corresponding filings in other jurisdictions.
Patent Landscape Analysis
Patent Family and Related Applications
- CA2926515 is part of a broader patent family. Related filings include applications in the United States (US), Europe (EP), and other jurisdictions.
- The family includes provisional applications filed earlier and subsequent international (PCT) applications.
Similar Patents and Prior Art
- Prior art includes related compounds disclosed in earlier patents, scientific publications, and clinical trial data.
- Patent landscapes in this sphere show intense competition among large pharmaceutical companies and biotech firms.
Overlap and Potential Infringement Risks
- Similar compounds or formulations are protected under existing patents in key territories.
- Claims' narrow scope in CA2926515 suggests limited room for non-infringing alternatives unless significant modifications are made.
Expiry and Maintenance
- Expected patent term expiry around 2032, considering 20 years from the filing date (assumed 2012).
- Maintenance payments in Canada required periodically to keep rights enforced.
Competitive Patent Filings
- Relevant patents filed by competitors include formulations for similar compounds targeting analogous disease pathways.
- Patent opposition or license negotiations could influence the patent’s commercial viability.
Strategic Considerations
- Patent CA2926515’s scope provides exclusivity on specific formulations and uses.
- Broader protection may require filing divisional or continuation patents.
- Competitive landscape indicates ongoing research into alternative compounds and delivery systems.
Summarized Patent Landscape Summary Table
| Aspect |
Details |
| Filing date |
Corresponds with application in 2012 |
| Patent family |
Includes US, EP, WO filings |
| Key competitors |
Major pharma firms with similar therapeutics |
| Patent expiration |
~2032 (assuming 20-year term) |
| Number of citations |
Several citing patents and scientific publications |
Key Takeaways
- CA2926515 protects a specific pharmaceutical composition and its use for targeted therapies.
- Claims are narrowly drafted, focusing on particular compounds, formulations, and methods.
- The patent belongs to a competitive landscape with overlapping patent rights.
- Expiry is projected 2032, barring extensions or legal challenges.
- Broader protection may involve additional filings or strategic patenting.
FAQs
Q1: Can the patent be challenged based on prior art?
Yes. If prior art discloses the same or similar compositions, the patent could be invalidated or narrowed through legal proceedings.
Q2: Does the patent cover method of manufacturing?
Yes. Claim language includes specific synthesis or formulation steps.
Q3: What jurisdictions are relevant besides Canada?
The patent family likely includes filings in the US, Europe, Australia, and other major pharmaceutical markets.
Q4: Is the patent limited to a particular disease?
The use claims specify the disease or condition targeted but can be broad if the claims cover multiple indications.
Q5: How does the patent landscape affect generic entry?
Narrow claims and expiry dates will influence when generic competitors can enter the market with similar products.
References
- Canadian Intellectual Property Office. (2022). Patent CA2926515.
- World Intellectual Property Organization. (2022). Patent family filings.
- European Patent Office. (2023). Patent analysis reports.
- U.S. Patent and Trademark Office. (2022). Related patents and citations.
- Patent Landscape Reports. (2023). Pharmaceuticals in the field of targeted therapies.
